淋巴结阳性宫颈癌根治性放化疗后序贯伊匹木单抗的1期试验
IMPORTANCE: Despite standard chemoradiotherapy (CRT), most women with lymph node (LN)-positive cervical cancer experience disease recurrence. Immunotherapy is being investigated in the up-front treatment setting.…
要点
- 放化疗后序贯伊匹木单抗在淋巴结阳性宫颈癌中耐受良好,最大耐受剂量10 mg/kg。
- 21例接受伊匹木单抗患者中仅2例(9.5%)出现自限性3级毒性。
- 12个月总生存率90%,无进展生存率81%。
核心结论
- 放化疗后序贯伊匹木单抗用于淋巴结阳性宫颈癌的根治性治疗耐受且有效。
- 放化疗后PD-1表达上调,序贯伊匹木单抗可维持该表达。
研究设计与样本
- 治疗方案为每周顺铂40 mg/m2共6次同步放疗,化疗结束后每21天给予伊匹木单抗共4次,剂量为3 mg/kg和10 mg/kg两个水平。
- 主要终点为安全性,次要终点为总生存和无进展生存,探索性终点包括HPV基因型、HLA等位基因状态和外周血PD-1表达。
主要发现
- 21例接受伊匹木单抗的患者中,2例(9.5%)出现自限性3级毒性(脂肪酶升高、皮炎)。
- 12个月总生存率为90%,无进展生存率为81%。
- HPV基因型和HLA亚型与无进展生存或总生存无关。
- 放化疗后表达PD-1的T细胞增加,且经伊匹木单抗治疗后维持该水平。
关键数值与推荐
- 最大耐受剂量为10 mg/kg。
- 21例接受伊匹木单抗的患者中,18例(86%)完成4周期,3例(14%)完成2周期。
- 21例接受伊匹木单抗的患者均有盆腔淋巴结阳性,其中6例(29%)有腹主动脉旁淋巴结阳性。
临床怎么用
- 对于淋巴结阳性宫颈癌,放化疗后序贯伊匹木单抗可作为耐受性良好的巩固免疫治疗策略。
- 治疗期间需监测脂肪酶和皮肤毒性,但本研究中3级毒性均为自限性。
- PD-1在放化疗后上调,提示序贯免疫治疗时机可能契合T细胞活化窗口。
局限性
- 本研究为1期试验,样本量小,主要目的是评估安全性。
- 13例入组患者未接受伊匹木单抗并被排除分析。
- 随访时间中位14.8个月,生存数据尚不成熟。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Despite standard chemoradiotherapy (CRT), most women with lymph node (LN)-positive cervical cancer experience disease recurrence. Immunotherapy is being investigated in the up-front treatment setting. OBJECTIVES: To assess the safety of sequential immunotherapy after CRT and to investigate human papillomavirus (HPV) genotype and HLA allele status on survival and programmed cell death 1 (PD-1) expression before and after CRT and sequential immunotherapy. DESIGN, SETTING, AND PARTICIPANTS: This prospective phase 1 trial conducted in 29 Gynecology Oncology Cooperative Group member institutions enrolled participants from December 18, 2012, to August 31, 2016, with a 14.8-month median follow-up and translational end points. Thirty-four women with International Federation of Gynecology and Obstetrics stage IB2 to IVA cervical cancer with positive pelvic LNs, para-aortic LNs, or both were enrolled; 13 did not receive ipilimumab and were excluded from the analysis. Data were analyzed from January 21 to April 4, 2018. INTERVENTIONS: Treatment consisted of 6 weekly doses of cisplatin, 40 mg/m2, concurrent with radiotherapy. After completion of chemotherapy, sequential ipilimumab was given every 21 days for 4 doses. Two dosage levels of ipilimumab, 3 mg/kg and 10 mg/kg, were studied to identify the maximum tolerated dose. MAIN OUTCOMES AND MEASURES: The primary end point was safety, and the secondary end points were overall survival and progression-free survival. Exploratory end points included HPV genotype, HLA allele status, and PD-1 expression measured in peripheral blood. RESULTS: The median age of the 32 participants included in the intent-to-treat analysis was 50 (range, 26-61) years, and 22 patients (69%) were white. Of the 21 patients who received ipilimumab, all had positive pelvic LN, and 6 (29%) had positive para-aortic LNs. All patients completed CRT, and of the 21 patients who received at least 2 cycles of ipilimumab, 18 (86%) completed 4 cycles of ipilimumab, and 3 (14%) completed 2 cycles. The maximum tolerated dose was 10 mg/kg. Two of the 21 patients (9.5%) who received ipilimumab had self-limiting grade 3 toxic effects (lipase increase; dermatitis). The 12-month overall survival was 90%, and progression-free survival was 81%. Human papillomavirus genotype and HLA subtype were not associated with progression-free survival or overall survival. T cells expressing PD-1 increased after CRT, and levels were sustained with ipilimumab. CONCLUSIONS AND RELEVANCE: This study's findings suggest that the use of immunotherapy after CRT for curative-intent treatment of patients with cervical cancer is tolerable and effective. The results indicated that PD-1 was upregulated after CRT and sustained with sequential ipilimumab therapy. These immune findings may help guide future therapies to harness the activated T-cell phenotype in patients with node-positive cervical cancer.
引用
- Mayadev JS, Enserro D, Lin YG, et al. Sequential Ipilimumab After Chemoradiotherapy in Curative-Intent Treatment of Patients With Node-Positive Cervical Cancer. JAMA Oncol. 2020. PMID: 31774464. doi:10.1001/jamaoncol.2019.3857
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。